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reamble
primary challenge in the development of clinical practice
idelines is keeping pace with the stream of new data on
hich recommendations are based. In an effort to respond
omptly to new evidence, the American College of Cardi-
ogy Foundation/American Heart Association (ACCF/AHA)
ask Force on Practice Guidelines (Task Force) has created a
ocused update” process to revise the existing guideline
commendations that are affected by the evolving data or
inion. Before the initiation of this focused approach,
riodic updates and revisions of existing guidelines required
to 3 years to complete. Now, however, new evidence will
reviewed in an ongoing fashion to more efficiently respond
important science and treatment trends that could have a
ajor impact on patient outcomes and quality of care.
vidence will be reviewed at least twice a year, and updates
ill be initiated on an as-needed basis and completed as
ickly as possible while maintaining the rigorous method-
ogy that the ACCF and AHA have developed during their
rtnership of more than 20 years.
These updated guideline recommendations reflect a con-
nsus of expert opinion after a thorough review primarily of
te-breaking clinical trials identified through a broad-based
tting process as being important to the relevant patient
pulation, as well as other new data deemed to have an
pact on patient care (see Section 1.1, Methodology and
vidence Review, for details). This focused update is not
tended to represent an update based on a full literature
view from the date of the previous guideline publication.
pecific criteria/considerations for inclusion of new data
clude the following:
publication in a peer-reviewed journal;
large, randomized, placebo-controlled trial(s);
nonrandomized data deemed important on the basis of
results affecting current safety and efficacy assumptions;
strength/weakness of research methodology and findings; mlikelihood of additional studies influencing current findings;
impact on current and/or likelihood of need to develop new
performance measure(s);
request(s) and requirement(s) for review and update
from the practice community, key stakeholders, and other
sources free of relationships with industry or other poten-
tial bias;
number of previous trials showing consistent results; and
need for consistency with a new guideline or guideline
revisions.
analyzing the data and developing the recommendations
d supporting text, the focused update writing group used
idence-based methodologies developed by the Task Force
at are described elsewhere (1). The committee reviewed and
nked evidence supporting current recommendations with
e weight of evidence ranked as Level A if the data were
rived from multiple randomized clinical trials or meta-
alyses. The committee ranked available evidence as Level
when data were derived from a single randomized trial or
nrandomized studies. Evidence was ranked as Level C
hen the primary source of the recommendation was consen-
s opinion, case studies, or standard of care. In the narrative
rtions of these guidelines, evidence is generally presented
chronological order of development. Studies are identified
observational, retrospective, prospective, or randomized
hen appropriate. For certain conditions for which inade-
ate data are available, recommendations are based on
pert consensus and clinical experience and ranked as Level
. An example is the use of penicillin for pneumococcal
eumonia, for which there are no randomized trials and
eatment is based on clinical experience. When recommen-
tions at Level C are supported by historical clinical data,
propriate references (including clinical reviews) are cited if
ailable. For issues where sparse data are available, a survey
current practice among the clinicians on the writing
mmittee was the basis for Level C recommendations and
references are cited. The schema for Classification of
ecommendations (COR) and Level of Evidence (LOE) is
mmarized in Table 1, which also illustrates how the grading
stem provides an estimate of the size and the certainty of
e treatment effect. A new addition to the ACCF/AHA
ethodology is a separation of the Class III recommendations
delineate whether the recommendation is determined to be
“no benefit” or associated with “harm” to the patient. In
dition, in view of the increasing number of comparative
fectiveness studies, comparator verbs and suggested phrases
r writing recommendations for the comparative effective-
ss of one treatment/strategy with respect to another for
OR I and IIa, LOE A or B only have been added.
The Task Force makes every effort to avoid actual, poten-
al, or perceived conflicts of interest that may arise as a result
relationships with industry and other entities (RWI) among
e writing group. Specifically, all members of the writing
oup, as well as peer reviewers of the document, are asked
disclose all current relationships and those existing 12onths before initiation of the writing effort. In response to
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e ACC and AHA, it is also required that the writing group
air plus a majority of the writing group (50%) have no
levant RWI. All guideline recommendations require a
nfidential vote by the writing group and must be approved
a consensus of the members voting. Members who were
cused from voting are noted on the title page of this
cument and in Appendix 1. Members must recuse them-
lves from voting on any recommendation to which their
WI apply. Any writing group member who develops a new
WI during his or her tenure is required to notify guideline
aff in writing. These statements are reviewed by the Task
ble 1. Applying Classification of Recommendations and Level
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use. A recommend
any important clinical questions addressed in the guidelines do not lend thems
ear clinical consensus that a particular test or therapy is useful or effective.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evid
rect comparisons of the treatments or strategies being evaluated.orce on Practice Guidelines and all members during each wnference call and/or meeting of the writing group and are
dated as changes occur. For detailed information about
ideline policies and procedures, please refer to the ACCF/
HA methodology and policies manual (1). Authors’ and
er reviewers’ RWI pertinent to this guideline are disclosed
Appendixes 1 and 2, respectively. In addition, to ensure
mplete transparency, writing group members’ comprehen-
ve disclosure information—including RWI not pertinent to
is document—is available online as a supplement to this
cument. Disclosure information for the Task Force is also
ailable online at www.cardiosource.org/ACC/About-ACC/
eadership/Guidelines-and-Documents-Task-Forces.aspx. The
ence
rent subpopulations, such as sex, age, history of diabetes, history of prior
th Level of Evidence B or C does not imply that the recommendation is weak.
clinical trials. Although randomized trials are available, there may be a very
and B only), studies that support the use of comparator verbs should involveof Evid
in diffe
ation wi
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ence: Aork of the writing group was supported exclusively by the
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mmercial support. Writing group members volunteered
eir time for this effort.
The ACCF/AHA practice guidelines address patient
pulations (and healthcare providers) residing in North
merica. As such, drugs that are currently unavailable in
orth America are discussed in the text without a specific
assification of recommendation. For studies performed in
rge numbers of subjects outside of North America, each
riting group reviews the potential impact of different
actice patterns and patient populations on the treatment
fect and the relevance to the ACCF/AHA target popula-
on to determine whether the findings should inform a
ecific recommendation.
The ACCF/AHA practice guidelines are intended to assist
althcare providers in clinical decision making by describ-
g a range of generally acceptable approaches for the
agnosis, management, and prevention of specific diseases
conditions. These practice guidelines represent a consensus
expert opinion after a thorough and systematic review of
e available current scientific evidence and are intended to
prove patient care. The guidelines attempt to define prac-
ces that meet the needs of most patients in most circum-
ances. The ultimate judgment regarding care of a particular
tient must be made by the healthcare provider and patient
light of all the circumstances presented by that patient.
hus, there are circumstances in which deviations from these
idelines may be appropriate. Clinical decision making
ould consider the quality and availability of expertise in the
ea where care is provided. When these guidelines are used
the basis for regulatory or payer decisions, the goal should
improvement in quality of care. The Task Force recognizes
at situations arise for which additional data are needed to
tter inform patient care; these areas will be identified within
ch respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
commendations are effective only if they are followed.
ecause lack of patient understanding and adherence may
versely affect outcomes, physicians and other healthcare
oviders should make every effort to engage the patient’s
tive participation in prescribed medical regimens and
festyles.
The recommendations in this focused update will be
nsidered current until they are superseded by another
cused update or the full-text guideline is revised. This
cused update is published in the Journal of the American
ollege of Cardiology, Circulation, and HeartRhythm as an
date to the full-text guideline, and it is also available on the
CC (www.cardiosource.org), AHA (my.americanheart.org),
d HRS (www.hrsonline.org) World Wide Web sites. A
vised version of the full-text guideline with links to the
cused update is e-published in the March 15, 2011, issues
the Journal of the American College of Cardiology and
irculation. For easy reference, this online-only version
notes sections that have been updated.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines no. Introduction
.1. Methodology and Evidence Review
he publication of the RE-LY (Randomized Evaluation of
ong-Term Anticoagulation Therapy) trial was considered
portant enough to prompt a focused update of the ACC/
HA/ESC 2006 Guidelines for the Management of Patients
ith Atrial Fibrillation (2). To provide clinicians with a
mprehensive set of data, whenever deemed appropriate or
hen published, the absolute risk difference and number
eded to treat or harm will be provided in the guideline,
ong with confidence intervals (CI) and data related to the
lative treatment effects such as odds ratio, relative risk
R), hazard ratio, or incidence rate ratio.
Consult the full-text version or executive summary of the
CC/AHA/ESC 2006 Guidelines for the Management of
atients With Atrial Fibrillation for policy on clinical areas
t covered by the focused update (2). The individual recom-
endations in this focused update will be incorporated into
ture revisions and/or updates of the full-text guideline.
.2. Organization of the Writing Committee
or this focused update, all eligible members of the 2006
trial Fibrillation Writing Committee were invited to partic-
ate; those who agreed (referred to as the 2011 Focused
pdate Writing Group) were required to disclose all RWI
levant to the data under consideration. The HRS was invited
be a partner on this update and provided 3 representatives.
.3. Document Review and Approval
his document was reviewed by 2 official reviewers each
minated by the ACCF, the AHA, and the HRS, and 5
dividual content reviewers (including members of the
CCF Electrophysiology Committee, the Atrial Fibrillation
erformance Measures Committee, and the Atrial Fibrillation
ata Standards Committee). All information on reviewers’
WI was collected and distributed to the writing committee
d is published in this report (Appendix 2).
This document was approved for publication by the gov-
ning bodies of the ACCF, AHA, and HRS.
. Management
his guideline update focuses on the use of dabigatran, a new
tithrombotic agent that was recently approved by the US
ood and Drug Administration (FDA), for the management of
tients with atrial fibrillation (AF).
1.4.2.5. RECOMMENDATION FOR USE OF ORAL DIRECT
HROMBIN INHIBITOR ANTICOAGULANT AGENTS. (See
able 2).
Dabigatran etexilate is a prodrug that is rapidly converted
the active direct thrombin (factor IIa) inhibitor dabigatran.
his conversion is independent of cytochrome P-450, making
ug-drug and drug-diet interactions less likely. Dabigatran is
edominantly excreted via a renal pathway. Dabigatran was
aluated in a large, open-label, randomized trial (RE-LY) in
hich it was compared with warfarin (goal international
rmalized ratio [INR] 2.0 to 3.0) in 18,113 patients with
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ses without laboratory monitoring of anticoagulation inten-
ty. Eligible participants had at least 1 risk factor for stroke
revious stroke or transient ischemic attack or systemic
bolism, left ventricular ejection fraction 40% or symp-
matic heart failure [New York Heart Association class II or
gher in the last 6 months], hypertension, age 75 years, or
e 65 to 74 years with either diabetes mellitus or coronary
tery disease). Exclusion criteria in RE-LY included a
osthetic heart valve or hemodynamically significant valvu-
r heart disease, disabling or recent stroke, recent or pending
rgery, recent or known bleeding disorders, uncontrolled
pertension, need for anticoagulation of disorders other than
F, planned ablation or surgery for AF, reversible causes
AF, severe renal dysfunction (creatinine clearance 30
L/min), active liver disease, or pregnancy. Two doses of
bigatran (110 mg and 150 mg twice daily) were evaluated.
he mean age of participants was 71 years, 63.6% were male,
lf had prior long-term therapy with vitamin K antagonists,
d the mean CHADS2 (Congestive heart failure, Hyperten-
on, Age, Diabetes, prior Stroke) risk prediction score
as 2.1. The primary outcome was all stroke (ischemic or
morrhagic) or systemic embolism; safety outcomes in-
uded bleeding, liver dysfunction, and other adverse events.
Results of the RE-LY trial were published in 2009 (3).
ates for the primary outcome of all stroke (ischemic or
morrhagic) or systemic embolism were 1.71% per year in
e warfarin group. Dabigatran etexilate, 150 mg twice daily,
duced the rate by 34% (to 1.11% per year; p0.001 for
periority; RR: 0.65; 95% CI: 0.52 to 0.81), and at this dose
ere was no increase in major bleeding (3). Dabigatran
exilate, 110 mg twice daily, was also associated with a rate
stroke and systemic embolism (1.54% per year) that was
ninferior to warfarin (p0.001 for noninferiority) (RR with
bigatran 0.90; 95% CI: 0.74 to 1.10), and at this dose there
as a 20% reduction in major bleeding risk compared with
arfarin (p0.003 for superiority). Rates of major bleeding
ere 3.57% per year for patients on warfarin, 2.87% per
ar for those on dabigatran 110 mg twice daily (p0.003),
d 3.32% per year for those on dabigatran 150 mg twice
ily (p0.32). In the warfarin group, INR values were
ithin the target range 64.4% of the time (4).
In addition, the results showed other secondary benefits
d adverse outcomes. For safety, both doses showed a
duction in life-threatening, intracranial, and total bleeding,
ble 2. Recommendation for Emerging Antithrombotic Agents
2011 Focused Update Recommendation Comments
ass I
Dabigatran is useful as an alternative to warfarin for
the prevention of stroke and systemic
thromboembolism in patients with paroxysmal to
permanent AF and risk factors for stroke or
systemic embolization who do not have a prosthetic
heart valve or hemodynamically significant valve
disease, severe renal failure (creatinine clearance
15 mL/min) or advanced liver disease (impaired
baseline clotting function) (3). (Level of Evidence: B)
New
recommendationcluding lower rates of intracerebral hemorrhage with both ul0 mg and 110 mg twice-daily doses (from 0.38% per year
the warfarin group to 0.12% per year with dabigatran 110
g twice daily [p0.001] and 0.10% per year with dabiga-
an 150 mg twice daily [p0.001]). Dyspepsia occurred
ore frequently with dabigatran (11.8% and 11.3% of pa-
ents in the low- [110 mg] and high- [150 mg] dose groups,
spectively) compared to warfarin (5.8% of patients). Also,
yocardial infarction was more frequent with dabigatran and
curred at rates of 0.82% (RR: 1.29; 95% CI: 0.96 to 1.75;
0.09) and 0.81% (RR: 1.27; 95% CI: 0.94 to 1.71;
0.12) with dabigatran, 110 mg and 150 mg twice daily,
spectively, and 0.64% with warfarin (3,4). Increased (3) or
creased (5) rates of myocardial infarction have been re-
rted with other oral thrombin inhibitors in different patient
pulations; however, the increase in myocardial infarction
en in RE-LY was not statistically significant in the dabiga-
an groups (4). In RE-LY, dabigatran did not cause hepato-
xicity (3). Drug discontinuation rates were slightly higher in
e dabigatran groups compared with warfarin. There was no
fference in mortality with dabigatran compared with war-
rin. Both dabigatran doses appeared to be noninferior to
arfarin with respect to the primary efficacy outcome of
roke or systemic embolism. In addition, the 150 mg twice-
ily dose was superior to warfarin with respect to stroke or
stemic embolism, and the 110 mg twice-daily dose was
perior to warfarin with respect to major bleeding. There is
specific antidote for dabigatran, which has a half-life of 12
17 hours. Supportive therapy for severe hemorrhage may
clude transfusions of fresh frozen plasma, packed red blood
lls, or surgical intervention if appropriate.
Because of the twice-daily dosing and greater risk of
nhemorrhagic side effects with dabigatran, patients already
king warfarin with excellent INR control may have little to
in by switching to dabigatran. Selection of patients with AF
d at least 1 additional risk factor for stroke who could
nefit from treatment with dabigatran as opposed to warfarin
ould consider individual clinical features, including the
ility to comply with twice-daily dosing, availability of an
ticoagulation management program to sustain routine mon-
oring of INR, patient preferences, cost, and other factors (6).
Dabigatran etexilate was approved by the FDA on October
, 2010, for marketing in the United States for the preven-
on of stroke and systemic embolism in patients with
nvalvular AF. A dose of 150 mg twice daily was approved
r patients with a creatinine clearance30 mL/min, whereas
patients with severe renal insufficiency (creatinine clear-
ce 15 to 30 mL/min) the approved dose is 75 mg twice
ily, a dose currently marketed in the European Union but
t evaluated in the RE-LY trial. There are no dosing
commendations for patients with creatinine clearance 15
L/min or patients on dialysis. The 110 mg twice-daily dose
ed in the RE-LY trial did not receive FDA approval. The
proval requires distribution of a medication guide with
ch prescription that details the risk of serious bleeding in
tients receiving dabigatran in this open-label (or “un-
inded”) trial (7). Dabigatran is the first new oral anticoag-
ant to become available for clinical use in 50 years.
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